ArticleOncology letters2016
Plasma lncRNA-GACAT2 is a valuable marker for the screening of gastric cancer.
Article in Oncology letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Abnormally Expressed lncRNAs as Potential Biomarkers for Gastric Cancer Risk: A Diagnostic Meta-Bioinformatics Analysis.BioMed research international · 2022Pooled it
- Circulating long noncoding RNAs as potential biomarkers for stomach cancer: a systematic review and meta-analysis.World journal of surgical oncology · 2021Pooled it
- Unlocking the power of non-coding RNAs: toward real-time cancer monitoring in precision oncology.Molecular cancer · 2026Review
- Multi-omics approach for identifying CNV-associated lncRNA signatures with prognostic value in prostate cancer.Non-coding RNA research · 2024Article
- The Mission of Long Non-Coding RNAs in Human Adult Renal Stem/Progenitor Cells and Renal Diseases.Cells · 2023Review
- Novel m7G-related lncRNA signature for predicting overall survival in patients with gastric cancer.BMC bioinformatics · 2023Article
- Blood-derived lncRNAs as biomarkers for cancer diagnosis: the Good, the Bad and the Beauty.NPJ precision oncology · 2022Review
- LncRNA GACAT2 binds with protein PKM1/2 to regulate cell mitochondrial function and cementogenesis in an inflammatory environment.Bone research · 2022Article
- Genetic instability-related lncRNAs predict prognosis and influence the immune microenvironment in breast cancer.Frontiers in genetics · 2022Article
- Association of lncRNA LINC01173 Expression with Vitamin-D and Vitamin B12 Level Among Type 2 Diabetes Patients.Diabetes, metabolic syndrome and obesity : targets and therapy · 2022Article
- One stomach, two subtypes of carcinoma-the differences between distal and proximal gastric cancer.Gastroenterology report · 2021Review
- Expression and mechanism of exosome-mediated A FOXM1 related long noncoding RNA in gastric cancer.Journal of nanobiotechnology · 2021Article
- Identification of Immune-Related LncRNA Pairs for Predicting Prognosis and Immunotherapeutic Response in Head and Neck Squamous Cell Carcinoma.Frontiers in immunology · 2021Article
- Review
- Long non-coding RNAs towards precision medicine in gastric cancer: early diagnosis, treatment, and drug resistance.Molecular cancer · 2020Review
- Noncoding RNAs in Extracellular Fluids as Cancer Biomarkers: The New Frontier of Liquid Biopsies.Cancers · 2019Review
- Long noncoding RNA HOXA11-AS promotes gastric cancer cell proliferation and invasionWorld journal of gastroenterology · 2019Article
- Recent advances in gastric cancer early diagnosis.World journal of gastroenterology · 2019Review
- Perineural invasion of cancer: a complex crosstalk between cells and molecules in the perineural niche.American journal of cancer research · 2019Review
- si-TP73-AS1 suppressed proliferation and increased the chemotherapeutic response of GC cells to cisplatin.Oncology letters · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long non-coding RNAs (lncRNAs) are crucial in contributing to gastric tumorigenesis and development. However, the diagnostic value of the majority of lncRNAs in gastric cancer (GC) are not clear. The present study investigated the diagnostic value of gastric cancer associated transcript 2 (GACAT2), a lncRNA that is aberrantly expressed in GC tissues. A total of 343 plasma samples from 80 healthy individuals, 29 patients with gastric dysplasia (GD) and 117 paired preoperative and postoperative patients with GC were collected. Plasma GACAT2 levels were subsequently measured by reverse transcription-quantitative polymerase chain reaction. Finally, the associations between plasma GACAT2 levels and various clinicopathological features of patients with GC were assessed. The results demonstrated that plasma GACAT2 levels in preoperative patients with GC were significantly higher than those in the postoperative group (P=0.031). Compared with healthy individuals, plasma GACAT2 levels were significantly increased in patients with GD (P<0.001) and preoperative patients with GC (P=0.040). Moreover, the individual relative changes of plasma GACAT2 expression following surgery were significantly associated with lymphatic metastasis (P=0.034), distal metastasis (P=0.035) and perineural invasion (P=0.039). Therefore, the results of the current study suggest that plasma-based GACAT2 may be developed as a tumor marker to screen and predict the prognosis of GC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.